>Mercado de medicamentos para el trastorno obsesivo compulsivo (TOC) de Asia y el Pacífico, por gravedad (leve a moderada, moderada a grave), subtipo ( obsesiones de contaminación con compulsión de lavado/limpieza, obsesiones de daño con compulsiones de comprobación, obsesiones sin compulsiones visibles, obsesiones de simetría con compulsiones de ordenar, organizar y contar, acaparamiento, otras), medicamentos ( antidepresivos , antipsicóticos, bloqueadores de NMDA, otros), vía de administración ( oral , parenteral), tipo de población (pediatría, adultos), usuario final (hospitales, clínicas especializadas, atención médica domiciliaria, otros), por canal de distribución (farmacia de hospital, farmacia minorista, farmacia en línea, otros), país (Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, Vietnam, resto de Asia y el Pacífico).
Análisis y perspectivas del mercado: mercado de medicamentos para el trastorno obsesivo-compulsivo (TOC) en Asia y el Pacífico
Se espera que el mercado de medicamentos para el trastorno obsesivo-compulsivo (TOC) de Asia y el Pacífico gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 10,2% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 232,74 millones para 2028. La creciente posición en el producto de medicamentos para el TOC con productos novedosos y una línea diversa de productos de medicamentos para el TOC son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.
El trastorno obsesivo-compulsivo (TOC) se refiere a un trastorno de ansiedad que se caracteriza por pensamientos y miedos irracionales e incontrolables que llevan a una persona a realizar comportamientos repetitivos. El trastorno obsesivo-compulsivo es un trastorno conocido por obligar a una persona a quedarse estancada en un pensamiento o miedo en particular. Se espera que los avances en el tratamiento, las terapias y los tratamientos novedosos, y los avances en los medicamentos ansiolíticos, antipsicóticos y antidepresivos brinden varias otras oportunidades en el mercado de medicamentos para el TOC. Sin embargo, la expiración de la patente de los medicamentos patentados y la introducción de versiones genéricas de medicamentos de marca son factores que se espera que limiten el crecimiento del mercado en el período de pronóstico.
El informe de mercado de medicamentos para el TOC proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsas de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un informe de analistas; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de medicamentos para el trastorno obsesivo-compulsivo (TOC) en Asia y el Pacífico
Obsessive-Compulsive Disorder (OCD) Drugs Market is segmented on the basis of severity, subtypes, drugs, route of administration, population, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of severity, the Asia-Pacific obsessive compulsive disorder (OCD) drugs market is segmented into mild to moderate and moderate to severe. In 2021, the moderate to severe segment is dominating the Asia-Pacific obsessive obsessive-compulsive disorder (OCD) drugs market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe are predicted to dominate the market.
- On the basis of subtype, the Asia-Pacific obsessive compulsive disorder (OCD) drugs market is segmented into contamination obsessions with washing/cleaning compulsion, harm obsessions with checking compulsions, obsessions without visible compulsions, symmetry obsessions with ordering, arranging, and counting compulsions, hoarding and others. In 2021, contamination obsessions with washing/cleaning compulsion is are dominating the Asia-Pacific obsessive obsessive-compulsive disorder drug market due to developments in the treatment, therapies, and introduction of novel treatments are predicted to dominate the market.
- On the basis of drugs, the Asia-Pacific obsessive compulsive disorder (OCD) drugs market is segmented into antidepressants, antipsychotics, NMDA blocker, and others. Antidepressants is further segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAS), and others. SSRIs is further segmented into fluvoxamine, fluoxetine, paroxetine, sertraline, and others. SNRIs is further segmented into duloxetine, venlafaxine and others. TCAS is further segmented into clomipramine, amitriptyline, imipramine, and others. Antipsychotics is further segmented into risperidone, haloperidol, quetiapine, olanzapine, aripiprazole, and others. NMDA blocker is further segmented into ketamine, memantine and others. In 2021, the antidepressants segment is dominating the Asia-Pacific obsessive obsessive-compulsive disorder drug market due to advancements in the anti-anxiety, antipsychotic and antidepressant drugs, and the robust pipelines for the development of newer treatment are predicted to dominate the market.
- On the basis of route of administration, the Asia-Pacific obsessive compulsive disorder (OCD) drugs market is segmented into oral and parenteral. Oral is further segmented into tablet, capsules and solution. In 2021, the oral segment is dominating the Asia-Pacific obsessive obsessive-compulsive disorder (OCD) drugs market due to novel treatment and advancements in therapies are predicted to dominate the market.
- On the basis of population, the Asia-Pacific obsessive compulsive disorder (OCD) drugs market is segmented into pediatrics and adults. In 2021, the adults segment is dominating the Asia-Pacific obsessive obsessive-compulsive disorder drug market due to research and development to enhance bioavailability, pharmacology, safety, and dosage parameters is are predicted to dominate the market.
- On the basis of end user, the Asia-Pacific obsessive compulsive disorder (OCD) drugs market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, the hospitals segment is dominating the Asia-Pacific obsessive obsessive-compulsive disorder drug market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe is predicted to dominate the market.
- On the basis of distribution channel, the Asia-Pacific obsessive compulsive disorder (OCD) drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is dominating the Asia-Pacific obsessive compulsive disorder drug market due to novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs are predicted to dominate the market.
- In Asia-Pacific, China is the dominat region due to technological advancement in treatment and diagnosis.
Obsessive-Compulsive Disorder (OCD) Drugs Market Country Level Analysis
The OCD drugs market is analyzed and market size information is provided on the basis of severity, subtypes, drugs, route of administration, population, end user and distribution channel.
The countries covered in the laxative market report are the Japan, China, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.
Hospitals segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of innovative R&D and new product launches and approvals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in research and development to enhance bioavailability, pharmacology, safety, and dosage parameters and Rise in Product Approvals are boosting the Market Growth of OCD drug products.
Obsessive-Compulsive Disorder (OCD) Drugs market also provides you with detailed market analysis for every country growth in OCD products industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2018.
Competitive Landscape and OCD Market Share Analysis
OCD drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to OCD drugs market.
The major companies which are dealing in the Obsessive-Compulsive Disorder (OCD) drugs are Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Amneal Pharmaceuticals LLC., H. LUNDBECK A/S, Apotex Inc., Teva Pharmaceutical industries Ltd. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Lannett, GlaxoSmithKline plc., Pfizer Inc., Mallinckrodt, Sebela Pharmaceuticals, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Lupin Pharmaceuticals, Inc., Dr. Reddy’s Laboratories Ltd., , Wockhardt, Alvogen, , Par Pharmaceutical, Abbott, Eli Lilly and Company, Viatria Inc., among others.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the OCD drugs market.
For instance,
- In June 2021, Sun Pharmaceutical Industries Limited announced that one of its wholly owned subsidiaries has entered into a license agreement with Ferring Pharmaceuticals Pvt. Ltd. (Ferring), a subsidiary of Switzerland-based biopharmaceuticals MNC Ferring Pharmaceuticals, to commercialize a Room Temperature Stable (RTS) formulation of obstetric drug, CARITEC® (Carbetocin RTS) in India. As per agreement terms, Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC®. Ferring has developed the drug and received approval from the Drugs Controller General of India (DCGI) for introducing the drug in India.
- In October 2019, Aurobindo Pharma Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Guaifenesin extended-release tablets, 600 mg and 1200 mg (OTC). Aurobindo’s Guaifenesin extended-release tablets are the AB rated generic equivalent of RB Health (US) LLC’s Mucinex® tablets.
- En agosto de 2020, Amneal Pharmaceuticals, Inc. anunció que recibió la aprobación de la Solicitud Abreviada de Nuevo Medicamento (ANDA) de la Administración de Alimentos y Medicamentos de los EE. UU. (FDA) para una versión genérica de Lidocaine Patch, 5%. Lidocaine Patch, 5% es la versión genérica de Lidoderm Patch, 5% para el tratamiento de la neuralgia posherpética.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de medicamentos para el TOC, lo que también proporciona el beneficio para que la organización mejore su oferta de productos de medicamentos para el TOC.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SEVERITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
6 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR OCD DRUGS
6.2 EUROPE REGULATORY FRAMEWORK FOR OCD DRUGS
6.3 AUSTRALIA REGULATORY GUIDANCE ON OCD DRUGS
7 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REIMBURSEMENT SCENARIO
8 COST ANALYSIS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.1.2 INCREASING CASES OF OBSESSIVE-COMPULSIVE DISORDER (OCD) WORLDWIDE
9.1.3 INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS
9.1.4 CHANGES IN LIFESTYLE AND ENVIRONMENTAL STRESS AMONG PEOPLE
9.1.5 INCREASING GENERIC APPROVALS
9.2 RESTRAINTS
9.2.1 RECALL OF DRUGS
9.2.2 ADVERSE EFFECTS OF DRUGS
9.2.3 STRINGENT GOVERNMENT REGULATIONS FOR OCD DRUGS DEVELOPMENT
9.2.4 UNAWARENESS AMONG PEOPLE OF EXISTENCE OF OCD
9.3 OPPORTUNITIES
9.3.1 TECHNOLOGICAL ADVANCEMENT FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.3.2 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS
9.3.3 RISE IN QUALITY CONCERNS
9.4 CHALLENGES
9.4.1 USE OF ALTERNATIVE THERAPIES
9.4.2 LIMITATIONS OF CURRENT OCD TREATMENT
10 IMPACT OF COVID-19 ON ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 MARKET BY DRUGS
11.1 TOTAL ADDRESSABLE MARKET
11.2 PATIENT POPULATION (2019-2028)
12 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY
12.1 OVERVIEW
12.2 MODERATE TO SEVERE
12.3 MILD TO MODERATE
13 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE
13.1 OVERVIEW
13.2 CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION
13.3 HARM OBSESSIONS WITH CHECKING COMPULSIONS
13.4 OBSESSIONS WITHOUT VISIBLE COMPULSIONS
13.5 SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS
13.6 HOARDING
13.7 OTHERS
14 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS
14.1 OVERVIEW
14.2 ANTIDEPRESSANTS
14.2.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS
14.2.1.1 FLUVOXAMINE
14.2.1.2 FLUOXETINE
14.2.1.3 PAROXETINE
14.2.1.4 SERTRALINE
14.2.1.5 OTHERS
14.2.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
14.2.2.1 DULOXETINE
14.2.2.2 VENLAFAXINE
14.2.2.3 OTHERS
14.2.3 TRICYCLIC ANTIDEPRESSANTS
14.2.3.1 CLOMIPRAMINE
14.2.3.2 AMITRIPTYLINE
14.2.3.3 IMIPRAMINE
14.2.3.4 OTHERS
14.3 ANTIPSYCHOTICS
14.3.1 RISPERIDONE
14.3.2 OLANZAPINE
14.3.3 ARIPIPRAZOLE
14.3.4 QUETIAPINE
14.3.5 HALOPERIDOL
14.3.6 OTHERS
14.4 NMDA BLOCKERS
14.4.1 MEMANTINE
14.4.2 KETAMINE
14.4.3 OTHERS
14.5 OTHERS
15 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULE
15.2.3 SOLUTION
15.3 PARENTERAL
16 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION
16.1 OVERVIEW
16.2 ADULTS
16.3 PEDIATRICS
17 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION
19.1 ASIA-PACIFIC
19.1.1 INDIA
19.1.2 JAPAN
19.1.3 CHINA
19.1.4 SOUTH KOREA
19.1.5 AUSTRALIA
19.1.6 SINGAPORE
19.1.7 MALAYSIA
19.1.8 THAILAND
19.1.9 INDONESIA
19.1.10 PHILIPPINES
19.1.11 VIETNAM
19.1.12 REST OF ASIA-PACIFIC
20 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 COMPANY SHARE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 H. LUNDBECK A/S
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 ELI LILLY AND COMPANY
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 APOTEX INC.
22.5.1 COMPANY SNAPSHOT
22.5.2 COMPANY SHARE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENTS
22.6 VIATRIS INC.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 LANNETT
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 GLAXOSMITHKLINE PLC
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENT
22.9 ALVOGEN
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 PFIZER INC.
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 AMNEAL PHARMACEUTICALS LLC
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENTS
22.12 DR.REDDY’S LABORATORIES LTD.
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 PRODUCT PORTFOLIO
22.12.4 RECENT DEVELOPMENTS
22.13 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENTS
22.14 ABBOTT
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 LUPIN PHARMACEUTICALS, INC.
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
22.16 MALLINCKRODT
22.16.1 COMPANY SNAPSHOT
22.16.2 REVENUE ANALYSIS
22.16.3 PRODUCT PORTFOLIO
22.16.4 RECENT DEVELOPMENTS
22.17 PAR PHARMACEUTICAL
22.17.1 COMPANY SNAPSHOT
22.17.2 REVENUE ANALYSIS
22.17.3 PRODUCT PORTFOLIO
22.17.4 RECENT DEVELOPMENTS
22.18 SEBELA PHARMACEUTICALS
22.18.1 COMPANY SNAPSHOT
22.18.2 PRODUCT PORTFOLIO
22.18.3 RECENT DEVELOPMENT
22.19 ZYDUS PHARMACEUTICALS USA INC. (A SUBSIDIARY OF ZYDUS CADILA)
22.19.1 COMPANY SNAPSHOT
22.19.2 REVENUE ANALYSIS
22.19.3 PRODUCT PORTFOLIO
22.19.4 RECENT DEVELOPMENTS
22.2 WOCKHARDT
22.20.1 COMPANY SNAPSHOT
22.20.2 REVENUE ANALYSIS
22.20.3 PRODUCT PORTFOLIO
22.20.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 BELOW MENTIONED ARE THE COST OF OCD DRUGS, AVAILABLE IN DIFFERENT DOSAGE FORMS SUCH AS A TABLET, CAPSULE, PARENTAL, AND STRENGTHS USED ASIA-PACIFICLY TO TREAT OBSESSIVE-COMPULSIVE DISORDER.
TABLE 2 DRUGS UNDER INVESTIGATIONS FOR OCD
TABLE 3 R&D COST BY KEY MARKET PLAYERS (USD MILLIONS) (2020)
TABLE 4 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC MODERATE TO SEVERE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC MILD TO MODERATE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC HARM OBSESSIONS WITH CHECKING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC OBSESSIONS WITHOUT VISIBLE COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC HOARDING IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC PARENTERAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC ADULTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC PEDIATRICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC HOSPITALS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC SPECIALTY CLINICS IN OBSESSIVE-COMPULSIVE (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC HOME HEALTHCARE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HOSPITAL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC RETAIL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC ONLINE PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC TRICYCLIC DEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 57 INDIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 58 INDIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 59 INDIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 60 INDIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 61 INDIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 62 INDIA SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 63 INDIA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 64 INDIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 65 INDIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 66 INDIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 INDIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 INDIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 69 INDIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 INDIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 JAPAN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 72 JAPAN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 73 JAPAN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 74 JAPAN ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 75 JAPAN SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 76 JAPAN SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 77 JAPAN TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 78 JAPAN ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 79 JAPAN NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 80 JAPAN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 JAPAN ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 JAPAN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 83 JAPAN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 JAPAN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 CHINA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 86 CHINA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 87 CHINA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 88 CHINA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 89 CHINA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 90 CHINA SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 91 CHINA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 92 CHINA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 93 CHINA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 94 CHINA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 CHINA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 CHINA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 97 CHINA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 98 CHINA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 100 SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 101 SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 102 SOUTH KOREA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 103 SOUTH KOREA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 104 SOUTH KOREA SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 105 SOUTH KOREA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 106 SOUTH KOREA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 107 SOUTH KOREA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 108 SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 SOUTH KOREA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 111 SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 112 SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 113 AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 114 AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 115 AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 116 AUSTRALIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 117 AUSTRALIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 118 AUSTRALIA SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 119 AUSTRALIA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 120 AUSTRALIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 121 AUSTRALIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 122 AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 AUSTRALIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 125 AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 SINGAPORE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 128 SINGAPORE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 129 SINGAPORE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 130 SINGAPORE ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 131 SINGAPORE SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 132 SINGAPORE SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 133 SINGAPORE TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 134 SINGAPORE ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 135 SINGAPORE NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 136 SINGAPORE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 SINGAPORE ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 SINGAPORE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 139 SINGAPORE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 140 SINGAPORE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 MALAYSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 142 MALAYSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 143 MALAYSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 144 MALAYSIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 145 MALAYSIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 146 MALAYSIA SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 147 MALAYSIA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 148 MALAYSIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 149 MALAYSIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 150 MALAYSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 MALAYSIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 MALAYSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 153 MALAYSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 154 MALAYSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 155 THAILAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 156 THAILAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 157 THAILAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 158 THAILAND ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 159 THAILAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 160 THAILAND SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 161 THAILAND TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 162 THAILAND ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 163 THAILAND NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 164 THAILAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 165 THAILAND ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 THAILAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 167 THAILAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 168 THAILAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 INDONESIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 170 INDONESIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 171 INDONESIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 172 INDONESIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 173 INDONESIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 174 INDONESIA SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 175 INDONESIA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 176 INDONESIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 177 INDONESIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 178 INDONESIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 179 INDONESIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 180 INDONESIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 181 INDONESIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 182 INDONESIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 183 PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 184 PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 185 PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 186 PHILIPPINES ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 187 PHILIPPINES SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 188 PHILIPPINES SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 189 PHILIPPINES TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 190 PHILIPPINES ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 191 PHILIPPINES NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 192 PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 193 PHILIPPINES ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 194 PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 195 PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 196 PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 197 VIETNAM OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 198 VIETNAM OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE, 2019-2028 (USD MILLION)
TABLE 199 VIETNAM OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 200 VIETNAM ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 201 VIETNAM SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 202 VIETNAM SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 203 VIETNAM TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 204 VIETNAM ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 205 VIETNAM NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 206 VIETNAM OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 VIETNAM ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 VIETNAM OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 209 VIETNAM OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 210 VIETNAM OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 211 REST OF ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 2 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET : ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 11 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER AND INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS ARE EXPECTED TO DRIVE THE ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 SEVERITY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUG MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES ABD CHALLENGES OF ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
FIGURE 14 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020
FIGURE 15 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020-2028 (USD MILLION)
FIGURE 16 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, CAGR (2021-2028)
FIGURE 17 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DIOSRDER (OCD) DRUG MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020
FIGURE 19 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020-2028 (USD MILLION)
FIGURE 20 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, CAGR (2020-2028)
FIGURE 21 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020
FIGURE 23 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020-2028 (USD MILLION)
FIGURE 24 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, CAGR (2020-2028)
FIGURE 25 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 29 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020
FIGURE 31 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020-2028 (USD MILLION)
FIGURE 32 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, CAGR (2021-2028)
FIGURE 33 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020
FIGURE 35 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 36 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 37 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 39 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 40 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 41 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 ASIA-PACIFIC ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: SNAPSHOT (2020)
FIGURE 43 ASIA-PACIFIC ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020)
FIGURE 44 ASIA-PACIFIC ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 45 ASIA-PACIFIC ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020 & 2028)
FIGURE 46 ASIA-PACIFIC ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY (2021-2028)
FIGURE 47 ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
